JACC Specialty Journals - podcast cover

JACC Specialty Journals

American College of Cardiologywww.jacc.org
In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.
Last refreshed:
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Download Metacast podcast app
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis | JACC: CardioOncology

This study analyzes over 2,600 transthyretin V142I variant carriers in the Million Veteran Program and finds significantly elevated risks of heart failure, cardiomyopathy, arrhythmias, neuropathy, and musculoskeletal complications compared with matched controls. Despite these risks, amyloidosis was rarely diagnosed clinically, underscoring major gaps in recognition and the need for earlier identification and multidisciplinary intervention.

Feb 17, 20263 min

Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact | JACC: CardioOncology

This study of 801 multiple myeloma patients found that atrial fibrillation occurred in 5.5% within 90 days after autologous stem cell transplantation—nearly double previously reported rates—indicating disease‑specific risks. AF strongly predicted mortality from non‑relapse causes and may serve as a marker of physiological vulnerability, emphasizing the value of expanded pre‑transplant cardiac assessment and monitoring.

Feb 17, 20263 min

CRISPR/Cas9 screens implicate RARA and SPNS1 in doxorubicin cardiotoxicity | JACC: CardioOncology

Researchers used genome‑wide CRISPR/Cas9 loss‑of‑function screens in cardiomyocytes to identify RARA and SPNS1 as key modulators of doxorubicin cardiotoxicity, highlighting pathways that influence both injury susceptibility and intracellular drug handling. Activation of RARA reduced toxicity without impairing anticancer effects, while SPNS1 loss caused harmful drug accumulation, offering new mechanistic insights and potential therapeutic targets.

Feb 17, 20263 min
Hosted on Libsyn
For the best experience, listen in Metacast app for iOS or Android